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Tumors of the salivary glands are uncommon head and neck neoplasia. We conducted a retrospective study of 392 cases over the
last 6 years in Shiraz, south of Iran, to investigate the clinicopathological features of these tumors in Iranian population. The age
of the patients ranged from 8 to 85 years, with the mean age 44.57 ± 14.65 years and male-to-female (M:F) ratio was 1.02:1.
For benign tumors, there was a propensity towards females, whereas the malignant tumor was more common in males. The
ratio of benign tumors to malignancies was 2.19:1. Pleomorphic adenoma (PA) was the most common tumor and accounted
for 85% of all benign tumors, followed by Warthin’s tumor (8.6%). Of the 125 malignancies, adenoid cystic carcinoma (40%),
mucoepidermoid carcinoma (24%) and invasive squamous cell carcinoma (16%) were the most common histological types.
Most of the salivary gland tumors (75%) originated from major salivary glands and the remained (25%) originated from minor
glands. The parotid gland was the most common site both in benign and malignant tumors. Most of our ﬁndings were similar to
those in the literature, with some variations. The salivary tumors slightly predominated in males. Adenoid cystic carcinoma and
mucoepidermoid carcinoma constituted the most common malignancies.
1.Introduction
Salivary gland tissues are diﬀusely distributed in the upper
aerodigestive tract. The parotid, submandibular, and sub-
lingual glands are the major salivary glands. Minor salivary
glands are present in many sites, such as the lips, gingiva,
cheek, palate, tongue, oropharynx, paranasal sinuses, and
parapharyngeal space. Salivary gland tumors are relatively
uncommon lesions accounting for 3–6% of all head and
neck neoplasms [1]. The global incidence of these tumors
is 0.4–13.5 per 100,000 persons annually [2–4]. These
neoplasms composed heterogeneous groups of tumors with
variable histological pictures. The site, patient age, and sex
distributions of diﬀerent types of salivary gland neoplasms
vary with race and geographic location. The incidence of
these tumors is diﬀerent in between geographic areas and
ethnic groups [2, 3, 5].
In the English literature, there is little report [1]o n
salivary gland tumors in Iranian population. The aim of this
study was to analyze the relative frequency, location, patient
sex, and age of salivary gland tumors in the southern Iranian
population over the last 6 years.
2.MaterialandMethods
This study included patients with primary epithelial salivary
gland neoplasms between 2004 to 2009, who underwent
operations in the Department of Maxillofacial Surgery,
Khalili Hospital, Shiraz. Hematoxylin-eosin- (H&E-) stained
slides of all cases were reviewed by two pathologists based2 Pathology Research International
Figure 1: Benign mixed tumor (pleomorphic adenoma) with a
biphasic admixture of epithelium and stroma (H&E ×200).
on the 2005 World Health Organization classiﬁcation of
h e a da n dn e c kt u m o r sc r i t e r i a[ 6]. Information regarding
age, gender, and anatomical location of the tumors was
collected from the patients’ hospital records. This research
was approved by the Ethics Committee of Shiraz University
of Medical Sciences. The data were analyzed for their
distribution of patient’s sex and age and anatomical location
of tumors.
3. Results
3.1. Histological Types. 392 patients underwent operations
for salivary gland tumors during this period. Among them,
267 (68.2%) were benign and 125 (31.8%) were malignant.
The ratio of benign tumors to malignancies was 2.19:1. The
distribution of histological patterns by anatomical locations
forbenignandmalignantsalivarytumorsisshowninTable1
and Figure 1,r e s p e c t i v e l y .
Pleomorphic adenoma (PA) was the most common
tumor and accounted for 85% (227/267) of all benign
tumors (Figure 1), followed by Warthin’s tumor (23/267,
8.6%). Myoepithelioma, basal-cell adenoma, and oncocy-
toma accounted for 4.5% (12/267), 1.1% (3/267) and 0.7%
(2/267) of benign tumors, respectively (Table 1).
Of the 125 malignancies, adenoid cystic carcinoma
(ACC, 50/125, 40%) (Figure 2), mucoepidermoid carci-
noma (MEC, 30/125, 24%), (Figure 3), and squamous cell
carcinoma (SCC, 20/125, 16%) were the most common
histological types, followed by acinic cell carcinoma (6/125,
4.8%), adenocarcinoma, not otherwise speciﬁed (NOS)
(5/125, 4%) and epithelial-myoepithelial carcinoma (4/125,
3%). Carcinoma ex-pleomorphic adenoma (2/125, 1%),
salivary duct carcinomas (2/125, 1%), polymorphous low-
grade adenocarcinoma (2/125, 1%) and basal-cell adeno-
carcinoma (2/125, 1%) were rare tumors. Twenty-two cases
of squamous cell carcinoma (22/125, 17%) was reported
in this series that all of them were direct invasion from
overlying skin or metastatic to intraparotid lymph nodes
(Table 1).
Figure 2: High-grade mucoepidermoid carcinoma composed of
squamous with few intermediate and clear cells (H&E ×200).
Table 1: Location and histological types of benign and malignant
salivary glands tumors.
Tumor type Number
(%)
Major
salivary gland
(n = 297)
Minor
salivary gland
(n = 95)
Pleomorphic adenoma 227 (58) 188 39
Warthins’ tumor 23 (6) 23 0
Myoepithelioma 12 (3) 7 5
Basal-cell adenoma 3 (0.7) 3 0
Oncocytoma 2 (0.6) 2 0
Mucoepidermoid
carcinoma 30 (8) 26 4
Adenoid cystic carcinoma 50 (13) 14 36
Adenocarcinoma NOS 5 (1) 0 5
Acinic cell carcinoma 6 (1.5) 5 1
carcinoma ex-pleomorphic
adenoma 2 (0.6) 0 2
Epithelial-myoepithelial
carcinoma 4( 1 ) 4 0
salivary duct carcinoma 2 (0.6) 2 0
Polymorphous low-grade
adenocarcinoma 2 (0.6) 1 1
Basal-cell adenocarcinoma 2 (0.6) 0 2
Squamous cell carcinoma
(Invasion from overlying
skin)
22 (5) 22 0
3.2. Locations. Most of the salivary gland tumors (297/392,
75%) originated from major salivary glands and the
remained (95/392, 25%) originated from minor glands
mainly located in the palate and lips. The parotid gland was
the most common site both in benign (175/297, 59%) and
malignant (56/125, 45%) tumors (Figure 2). Most of the
tumors in the minor salivary glands were malignant rather
than benign (53/34) and the palate was the most frequent
location for minor gland tumors. Among benign tumors,
almost all Warthin’s tumors (100%), oncocytomas (100%),Pathology Research International 3
Table 2: Comparison of reported distribution of salivary gland tumors in south of Iran and other countries.
Total Benign Malignant PA ACC MEC Reference
Current study 392 267 (68) 124 (32) 227 (58) 50 (13) 30 (8) —
Iran, west 130 89 (68) 41 (32) 85 (65) 3 (2) 15 (11) [1]
China 6982 4743 (68) 2239 (32) 3281 (47) 681 (10) 673 (10) [4]
UK 741 481 (65) 260 (35) 329 (44) 62 (8) 85 (11) [7]
Italy 454 405 (89) 49 (11) 287 (63) 8 (2) 15 (3) [8]
Jordan 221 151 (68) 70 (32) 139 (63) 12 (5) 38 (17) [2]
Congo 275 180 (65) 95 (35) 152 (55) 44 (16) 22 (8) [9]
Brazil 496 335 (68) 161 (32) 269 (54) 39 (8) 67 (14) [10]
Uganda 268 145 (54) 123 (46) 107 (40) 36 (13) 25 (9) [11]
USA 218 198 (90) 20 (9) 137 (62) 0 (0) 20 (9) [12]
Bratislava 767 649 (85) 118 (15) 550 (71) 65 (8) 53 (6) [13]
Nigeria 78 44 (56) 34 (43) 37 (49) 1 (1) 18 (23) [14]
Sri Lanka 713 356 (50) 356 (50) 274 (38) 96 (13) 154 (22) [15]
India 684 422 (62) 262 (38) 588 (86) 123 (18) 171 (25) [16]
Figure 3: Adenoid cystic carcinoma, nests of cells of rather bland
appearance are arranged concentrically around gland-like spaces
(H&E ×200).
basal-cell adenomas (100%), and most myoepitheliomas
(60%) were located in the parotid gland.
Among the malignancies, ACC and MEC were the most
common types. ACC more frequently occurred in minor
salivaryglands,buttheMECwasmorecitedinmajorsalivary
glands. Neither malignant nor benign tumors possessed
a dominance of left- or right-side involvement. Bilateral
involvement was not present in this study.
3.3. Age and Sex. Among 392 patients with salivary gland
tumors, 198 were male, and 194 were female; the male-to-
female (M:F) ratio was 1.02:1. For benign tumors, there
was a propensity towards females (130/137, M:F = 0.9:1),
whereas the malignant tumors were more common in males
(68/57, M:F = 1.1:1), (Figure 2).
The age of the patients in this study ranged from 8 to
85 years, with the mean ± SD = 44.57 ± 14.65 years. The
peak incidence for both benign and malignant salivary gland
tumors was the ﬁfth decade of life (Figure 3).
The peak incidence of PA is the fourth to sixth decades.
Warthin’s tumor is more prevalent in the 5-6th decade, and
the oncocytoma and basal-cell adenoma are more common
in fourth decade of life. For malignant tumors, the highest
incidences of MEC and ACC were all in the ﬁfth to sixth
decade of life.
The total number of tumors (benign and malignant)
occurring in young people under 20 years was 31, represent-
ing 8% of all tumors. In this age group, benign tumors were
predominant (Figure 3), and PA was the most common type
of tumor (23/31, 74%), followed by ACC (4/31, 12%). The
ACC was the most commontype of malignant tumors in this
age group.
4. Discussion
Khalili Hospital is the largest referral hospital for max-
illofacial tumors in the south of Iran, and many salivary
gland tumors are treated in this hospital. In this study,
benign salivary gland comprised 68% of all salivary tumors
and predominated in major glands, similar to the rates
reported by authors in the west of Iran, China, Jordan,
UK, USA, India, Brazil, Nigeria, Congo, Uganda, Bratislava,
and Sri Lanka [1, 2, 4, 7, 9–12, 14]( T a b l e2). In all these
reports from diﬀerent countries, benign tumors accounted
for more than 50% of all salivary tumors, suggesting that
benign tumors are predominant in salivary gland tumors
worldwide.
In this study, PA was the most common type of salivary
gland tumor (58%). This was consistent with other reports
from diﬀerent parts of the world, which have considered
prevalence rates for PA between 40–65% (Table 2). The
majority of PA was in major salivary glands. This ﬁnding
was similar to a WHO report [6], in which approximately
80% of all PAs were occurred in the parotid gland, and 10%
developed in the various minor glands.
The second most common benign tumor in this study,
Warthin’s tumor, comprised 23% of all salivary tumors,4 Pathology Research International
which was less than the prevalence in Denmark and parts
of Pennsylvania (about 30% of parotid tumors) [17, 18].
This tumor was rare in African populations [11]. Most
of these tumors occurred in males (78%), and the M:F
ratio was 3.6:1. Previous studies mentioned an increas-
ing incidence of Warthin’s tumor in females during the
past 50 years, and the M:F ratio changed from 10:1 to
1.2:1, which may be related to the increased numbers
of female smokers [6, 17]. In this study the majority of
patients with Warthin’s tumor had a history of tobacco
smoking.
The reported frequencies for malignant salivary gland
ranged were between 10–46%, and the MEC was the most
common malignant tumor, with a prevalence ranging from
4–12% [6]( T a b l e2). Our data showed that malignancies
comprised 32% of all salivary gland, and the ACC was
the most common one (13%). The overall incidence of
malignant tumors was similar to those reported from west
of Iran and other countries [1, 2, 4, 7, 9–12, 14]. The
higher prevalence of ACC was near the reported incidence
from China and Congo [4, 9], but in the west of Iran,
China, Jordan, UK, USA, India, Brazil, Nigeria, Uganda,
and Bratislava the frequency of MEC was higher than that
of ACC, and MEC was the most common malignancy
(Table 2). These ﬁndings suggest a geographic variation in
the frequencies of ACC and MEC. However, our report
was diﬀerent from Buchner et al. ﬁndings. They studied
relative frequency of intraoral minor salivary gland tumors
in northern California, USA. MEC was the most com-
mon (21.8%), followed by PLGA (7.1%) and ACC (6.3%)
[19]. According to WHO classiﬁcation of salivary gland
tumors 2005, PLGA is the second more common malignant
tumor of minor salivary gland, being surpassed only by
MEC.
Most studies [6, 7, 10] revealed that the occurrence of
salivary gland tumors was slightly higher in females. In the
present study, males were slightly more aﬀected (M:F =
1.02:1) like the ﬁnding in previous study [4]. The reason
for this was the signiﬁcant male predominance for Warthin’s
tumor and SCC.
In summary, this study was an epidemiological analysis
of salivary gland tumors in the south Iranian population.
Most of the ﬁndings about the distribution of histological
type, age, and sex in this population were similar to those
reported in the literature. However, there were few racial and
geographic variations in the frequency and distribution of
tumors between this study and other populations. PA was
the most common benign and ACC ranked as the most
common malignant salivary gland tumors followed by MEC.
The overall occurrence of salivary gland tumors was slightly
higher in males.
The reason for these diﬀerences remains unclear. There-
fore, more research on this ﬁeld is greatly encouraged.
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